3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
3
Neoplasm Metastasis
2
Breast Neoplasms
2
Sarcoma, Synovial
1
Sarcoma
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
Dermatofibrosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Doxorubicin
62
Ifosfamide
39
Gemcitabine
29
Radiotherapy
27
Filgrastim
27
Cyclophosphamide
26
Docetaxel
19
Vincristine
18
pembrolizumab
17
Etoposide
17
pazopanib
16
Cisplatin
16
Nivolumab
15
Trabectedin
14
apatinib
13
Magnetic Resonance Spectroscopy
13
Carboplatin
12
Irinotecan
11
Bevacizumab
11
Temozolomide
10
Sirolimus
10
camrelizumab
9
anlotinib
9
Surgical Procedures, Operative
9
Sorafenib
9
Paclitaxel
9
Ipilimumab
9
Injections
9
Dactinomycin
9
Topotecan
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma
×
Quality of Life
×
Clear all
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled